The Japan Academy

Personal Information

 

Name

UEDA Ryuzo

 

Section

Section II, Seventh Subsection

Date of Election

2024/12/12

Speciality

Internal Medicine, Clinical Oncology, Hematology Oncology

Selected Bibliography

Original articles

  1. 1. Ueda R, Shiku H, Pfreundschuh M, Takahashi T, Li ITC, Whitmore WF, Oettgen HF, Old LJ: Cell surface antigens of human renal cancer defined by autologous typing.
    J Exp Med, 150 (3): 564-579, 1979.
  2. Ueda R, Ogata S, Morrissey DM, Finstad CL, Szkudlarek J, Whitmore WF, Oettgen HF., Lloyd KO. Old LJ.: Cell surface antigens of human renal cancer defined by mouse monoclonal antibodies: Identification of tissue-specific kidney glycoproteins. Proc Natl Acad Sci USA, 78 (8): 5122-5126, 1981.
  3. Ueda R, Tanimoto M, Takahashi T, Ogata S, Nishida K, Namikawa R, Nishizuka Y, Ota K: Serological analysis of cell surface antigens of null cell acute lymphocytic leukemia by mouse monoclonal antibodies. Proc Natl Acad Sci USA, 79 (14): 4386-4390, 1982.
  4. Ueda R, Nishida K, Koide Y, Tsuge I, Seto M, Yoshida M, Miyoshi I, Ota K, Takahashi T: Two mouse monoclonal antibodies detecting two different epitopes of an activated lymphocyte antigen on adult T-cell leukemia cells. Cancer Res, 45 (3): 1314-1319, 1985.
  5. Takahashi T, Ueda R, Song X, Nishida K, Shinzato M, Namikawa R, Ariyoshi Y, Ota K, Kato K, Nagatsu T, Imaizumi M, Abe T, Takahashi T: Two novel cell surface antigens on small cell lung carcinoma defined by mouse monoclonal antibodies NE-25 and PE-35. Cancer Res, 46 (9): 4770-4775, 1986.
  6. Motoi T, Uchiyama T, Hori T, Itoh K, Uchino H, Ueda R: Elevated serum-soluble interleukin-2 receptor (Tac antigen) levels in chronic myelogenous leukemia patients with blastic crisis. Blood, 74 (3): 1052-1057, 1989.
  7. Takahahsi T, Takahashi T, Suzuki H, Hida T, Sekido Y, Ariyoshi Y, Ueda R: The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene, 6 (10): 1775-1778, 1991.
  8. Namikawa R, Ueda R, Kyoizumi S: Growth of human myeloid leukemias in the human marrow environment of SCID-hu mice. Blood, 82 (8): 2526-2536, 1993.
  9. Suzuki H, Ueda R, Takahashi T, Takahashi T: Altered imprinting in lung cancer.  Nat Genet, 6 (4): 332-333, 1994.
  10. Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, Takeuchi G, Shimizu S, Ito M, Komatsu H, Wakita A, Eimoto T, Matsushima K, Ueda R:  Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res, 9 (10 Pt 1): 3625-3634, 2003.
  11. Niwa R, Shoji-Hosaka E, Sakurada M, Shinkawa T, Uchida K, Nakamura K, Matsushima K, Ueda R, Hanai N, Shitara K: Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res, 64 (6): 2127-2133, 2004.
  12. Ishida T, Iida S, Akatsuka Y, Ishii T, Miyazaki M, Komatsu H, Inagaki H, Okada N, Fujita T, Shitara K, Akinaga S, Takahashi T, Utsunomiya A, Ueda R: The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma. Clin Cancer Res, 10 (22): 7529-7539, 2004.
  13. Yano H, Ishida T, Inagaki A, Ishii T, Ding J, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R: Defucosylated anti-CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome. Clin Cancer Res, 13 (21): 6494-6500, 2007.
  14. Ito A, Ishida T, Utsunomiya A, Sato F, Mori F, Yano H, Inagaki A, Suzuki S, Takino H, Ri M, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R: Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo. J Immunol, 183 (7): 4782-4791, 2009.
  15. Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, Yamaguchi K, Yamada Y, Hanada S, Tamura K, Nakamura S, Inagaki H, Ohshima K, Kiyoi H, Ishida T, Matsushima K, Akinaga S, Ogura M, Tomonaga M, Ueda R: Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol, 28 (9): 1591-1598, 2010.
  16. Ishida T, Ueda R: Immunopathogenesis of lymphoma: focus on CCR4. Cancer Sci, 102 (1): 44-50, 2011.
  17. Ishida T, Ueda R. Antibody therapy for Adult T-cell leukemia-lymphoma.　Int J Hematol, 94 (5): 443-452, 2011.
  18. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, Saburi Y, Miyamoto T, Takemoto S, Suzushima H, Tsukasaki K, Nosaka K, Fujiwara H, Ishitsuka K, Inagaki H, Ogura M, Akinaga S, Tomonaga M, Tobinai K, Ueda R:  Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol, 30 (8): 837-842, 2012.
  19. Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R: Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol, 32 (11): 1157-1163, 2014.
  20. Kurose K, Ohue Y, Wada H, Iida S, Ishida T, Kojima T, Doi T, Suzuki S, Isobe M, Funakoshi T, Kakimi K, Nishikawa H, Udono H, Oka M, Ueda R, Nakayama E: Phase Ia study of FoxP3+ CD4 Treg depletion by Infusion of a humanized anti-CCR4 antibody, KW-0761, in cancer patients. Clin Cancer Res, 21 (19): 4327-4336, 2015.
  21. Sakamoto Y, Ishida T, Masaki A, Murase T, Yonekura K, Tashiro Y, Tokunaga M, Utsunomiya A, Ito A, Kusumoto S, Iida S, Ueda R, Inagaki H: CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment. Blood, 132 (7): 758-761, 2018.
  22. Maeda Y, Wada H, Sugiyama D, Saito T, Irie T, Itahashi K, Minoura K, Suzuki S, Kojima T, Kakimi K, Nakajima J, Funakoshi T, Iida S, Oka M, Shimamura T, Doi T, Doki Y, Nakayama E, Ueda R, Nishikawa H: Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab. Nat Commun, 12 (1): 7280, 2021.
  23. Fujikawa K, Saito T, Kurose K, Kojima T, Funakoshi T, Sato E, Kakimi K, Iida S, Doki Y, Oka M, Ueda R, Wada H. Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors. PLoS One. Sep 20;18(9): e0291772, 2023.